33 studies on Hexarelin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 77 published Hexarelin COA source records from third-party laboratories, covering 43 publicly attributable vendor identities. Across 62 records with positive numeric purity, the arithmetic mean is 99.36%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 5 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-07. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 2 mg | $5.50 | $5.50–$5.50 | $2.75 | 1 source · 1 offer |
| 5 mg | $13.50 | $12.50–$14.50 | $2.70 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-07. Aggregate calculated: 2026-10-18T15:38:51.993164+00:00. Calculation time is not a laboratory observation date.
Within that total, 23 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 2 | 99.63% | 0 of 2 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 3 | 99.6% | 0 of 2 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → | |
| #3 | 2 | 99.45% | 0 of 2 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #118482 (99.63%) · #114507 (99.67%) · #110112 (99.49%) · #89539 (99.47%) · #80135 (99.63%) · #66483 (99.76%)
This research validates the ZWT model as a powerful, cost-effective tool for preclinical metabolism screening, including for peptides like hexarelin. For researchers and developers, this provides an alternative pathwa…
The discovery of a third ghrelin receptor with distinct properties highlights the greater complexity of the ghrelin system, at least in fish. For researchers and biohackers, this implies that synthetic GHS peptides li…
This research clarifies a key mechanism behind Hexarelin's cardioprotective effects, positioning the `PTEN`/`Akt`/`mTOR` pathway as a direct target. For peptide users or clinicians exploring therapies for cardiac reco…
This research provides a specific molecular mechanism for hexarelin's known cardioprotective effects, linking it directly to the modulation of autophagy via the `mTOR` pathway. For researchers and biohackers exploring…
This research highlights a critical limitation of common permeation enhancers for oral peptide delivery. The finding that enhancers effective for small peptides completely fail for a larger peptide like hexarelin sugg…
This research provides a mechanistic basis for hexarelin's cardioprotective effects, specifically highlighting its role in modulating macrophage behavior—a key driver of atherosclerotic plaque formation. For peptide u…
This research provides compelling evidence for hexarelin as a potential therapeutic agent to mitigate heart damage following a heart attack. For individuals interested in cardiac recovery protocols, **hexarelin demons…
This study provides evidence that activating the `GHSR` to enhance the body's natural, pulsatile GH release pattern is a viable strategy for managing obesity and its metabolic complications. For individuals exploring …
These findings establish that hexarelin has direct neuroprotective and anti-apoptotic effects in a cellular model of oxidative stress. For researchers and biohackers interested in neuroprotection, this suggests hexare…
This research provides a proof-of-concept for improving the oral bioavailability of larger peptides like **hexarelin** by targeting the paracellular pathway. For individuals using oral peptide formulations, this sugge…
This research highlights Hexarelin's potential as a novel therapeutic agent for abdominal aortic aneurysm (AAA), a life-threatening condition with limited pharmacological treatments. By simultaneously addressing both …
This research highlights Hexarelin's potential as a potent neuroprotective agent for conditions involving retinal ganglion cell (RGC) loss. Given the devastating impact of optic neuropathies on vision, finding compoun…
The results suggest a potential clinical application for `GHS-R` agonists like hexarelin as adjuncts to opioid therapy. **By co-administering hexarelin with morphine, it may be possible to use lower doses of opioids, …
**Any consumer purchasing this supplement was unknowingly ingesting a WADA-prohibited peptide capable of stimulating the hGH/IGF-1 axis**, with no dosing guidance, safety oversight, or disclosure. For athletes, a posi…
**Clinicians managing thalassemia-related growth failure** should note that standard stimulation testing may miss subnormal ultradian GH secretion, meaning affected patients could benefit from secretagogue-based proto…
This comprehensive review underscores the broad therapeutic potential of GHS across multiple organ systems and conditions. The observed benefits, from cardioprotection and growth promotion to metabolic improvements an…
**GHRPs — particularly hexarelin — should be understood as direct cardiac agents**, not merely GH secretagogues; clinicians and researchers evaluating these compounds for body composition or GH-axis support must accou…
**Hexarelin and MK-0677 do not bind to the same receptor populations in peripheral tissues** — a distinction with direct implications for anyone selecting between peptidyl and non-peptidyl GHS compounds. For cardiovas…
**The octanoyl fatty-acid modification on ghrelin is non-negotiable for receptor engagement**, directly validating why unacylated ghrelin fragments lack GH-releasing potency. For clinicians and researchers, this confi…
**The endocardial endothelium is a required intermediary for hexarelin's cardiac effects**, which reframes hexarelin as an endothelium-targeting agent rather than a direct myocardial inotrope. For clinicians and resea…
**Oral bioavailability combined with significant anabolic output** positions SM-130686 in the same practical niche as MK-677 but with a structurally novel scaffold — potentially relevant for researchers seeking altern…
**Peptidyl GHS compounds like hexarelin may carry direct anticancer activity in lung carcinoma independent of their GH-releasing function**, a mechanistic split with major implications for therapeutic development and …
**The cardioprotection afforded by ghrelin and hexarelin appears to be independent of growth hormone secretion**, meaning GH-axis side effects are unlikely to be required for — or necessarily coupled to — the cardiac …
**Des-acyl ghrelin is not metabolically inert** — it directly suppresses fat breakdown at nanomolar concentrations equal to acylated ghrelin, fundamentally revising how practitioners should interpret circulating ghrel…
**Anti-doping laboratories now have a validated, multi-analyte LC-MS protocol** covering the eight most relevant GHRP candidates in a single urine assay, filling a critical gap left by GH immunoassays. The 20 h metabo…
This advanced analytical method significantly enhances anti-doping efforts by providing a highly sensitive, robust, and expandable tool for detecting a broad panel of small prohibited peptides. The ability to detect t…
This advanced analytical method provides a crucial tool for anti-doping agencies to combat the illicit use of GHRPs in both equine and human sports. By enabling reliable and high-throughput detection, it helps ensure …
These findings directly inform and improve anti-doping testing protocols. By identifying specific, long-lasting metabolites for each GHRP, labs can create more robust screening methods that significantly extend the de…
This research provides a foundational understanding of which structural parts of GHRPs like Ipamorelin are critical for their function. For peptide users, this knowledge explains why certain analogues are more or less…
For anti-doping analysts and forensic toxicologists, this study validates a practical and ethical method for identifying new biomarkers of peptide abuse. Instead of relying on difficult-to-conduct human trials, labs c…
Free, no account — handy when you're working with Hexarelin.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account